ERBB2 and breast cancer: Tumors classified as HER2- IHC 1+/2+, ISH non-amplified have been recently defined as “HER-2 low-masked” or simply “HER2 low-positive”, representing about 45–55% of HER2-negative BC cases [26,29,59,60].